Authors: Van Hecken, A Schwartz, JI Depre, M De Lepeleire, I Dallob, A Tanaka, W Wynants, K Buntinx, A Arnout, J Wong, PH Ebel, DL Gertz, BJ De Schepper, PJ

Citation: A. Van Hecken et al., Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers, J CLIN PHAR, 40(10), 2000, pp. 1109-1120

Authors: Depre, M Ehrich, E Van Hecken, A De Lepeleire, I Dallob, A Wong, P Porras, A Gertz, BJ De Schepper, PJ

Citation: M. Depre et al., Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans, EUR J CL PH, 56(2), 2000, pp. 167-174

Authors: Dallob, A De Lepeleire, I Van Hecken, A Porras, A Depre, M Mukhopadhyay, S Flynn, M Wildonger, L Gottesdiener, K Tanaka, W De Schepper, P

Citation: A. Dallob et al., Ex vivo assays demonstrate potency and selectivity of the COX-2 inhibitor DFP after single dose administration, INFLAMM RES, 48, 1999, pp. S130-S131

Authors: Depre, M Van Hecken, A Verbesselt, R Wynants, K De Lepeleire, I Freeman, A Holland, S Shahane, A Gertz, B De Schepper, PJ

Citation: M. Depre et al., Effect of multiple doses of montelukast, a cysLT(1) receptor antagonist, on digoxin pharmacokinetics in healthy volunteers, J CLIN PHAR, 39(9), 1999, pp. 941-944

Authors: Van Hecken, A Depre, M Verbesselt, R Wynants, K De Lepeleire, I Arnout, J Wong, PH Freeman, A Holland, S Gertz, B De Schepper, PJ

Citation: A. Van Hecken et al., Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers, J CLIN PHAR, 39(5), 1999, pp. 495-500